PPD Awarded U.S. Army Contract to Support Biodefense and Vaccine Development Programs

Providing global regulatory and biostatistical services for broad range of drug development initiatives

WILMINGTON, N.C. (May 31, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced it has been awarded the U.S. Army Medical Research Acquisition Activity: Regulatory Affairs & Compliance Support contract to provide global regulatory and biostatistical services for a range of clinical development programs funded by the U.S. Army.

The award is a multi-year, indefinite delivery, indefinite quantity (IDIQ) contract with a ceiling value of $45.5 million over a five-year period beginning April 15, 2011.

PPD brings strong operational regulatory capacity, regulatory affairs consulting expertise, and an in-depth understanding of global regulatory requirements and submission strategies to aid the U.S. Army in preparing and filing clinical trial submissions to the U.S. Food and Drug Administration and other regulatory authorities worldwide. PPD's quality assurance and medical writing professionals will ensure regulatory compliance for the U.S. Army's clinical programs and support biodefense, biopreparedness and vaccine development initiatives aimed at protecting military personnel.

In addition, PPD's team of global biostatisticians will provide statistical consulting, study design and statistical analysis support.

"This contract enables us to deliver on our breadth of global regulatory and biostatistics services and assist the U.S. Army in advancing clinical programs that improve the health of men and women serving in our armed forces," said Henrietta Ukwu, M.D., senior vice president of global regulatory affairs for PPD. "We are pleased to partner with the U.S. Army in this effort and to continue to extend our long history of partnering with the U.S. Government on clinical research and development."

PPD has delivered global clinical support services to U.S. Government research and development programs for 21 years. The company has collaborated on more than 900 government and public health drug development projects in multiple indications, including infectious diseases, vaccines, biodefense, and autoimmune and asthma/allergic diseases.

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.